Solid Tumors Dependent on KIT or PDGFRA Signaling research hub

A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling

This study is looking at a new medicine called Avapritinib for children and young people with certain types of solid tumours. It aims to find the right dose, see how safe it is, and if it can help shrink or control the cancer. It's an early-stage study to understand the drug better.